Sign in →

Test Code CXCFX MYD88 Reflex to CXCR4 Mutation Detection, Varies


Specimen Required


Only orderable as a reflex. For more information see LPLFX / Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia, MYD88 L265P with Reflex to CXCR4, Varies.


Useful For

The prognosis and clinical management of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia

Method Name

Only orderable as a reflex. For more information see LPLFX / Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia, MYD88 L265P with Reflex to CXCR4, Varies.

 

Bridged Nucleic Acids (BNA) Clamp Sanger Sequencing/Routine Sanger Sequencing

(BNAClamp is utilized pursuant to a license agreement with BNA Inc.)

Reporting Name

CXCR4, Gene Mutation, Reflex

Specimen Type

Varies

Specimen Minimum Volume

Whole blood, Bone marrow: 1 mL; Extracted DNA: 20 mcL with a concentration of at least 10 nanograms per mcL

Specimen Stability Information

Specimen Type Temperature Time
Varies Varies 10 days

Reference Values

Only orderable as a reflex. For more information see LPLFX / Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia, MYD88 L265P with Reflex to CXCR4, Varies.

 

An interpretive report will be provided

Interpretation

Mutation present or not detected; an interpretive report will be issued under LPLFX / Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia, MYD88 L265P with Reflex to CXCR4, Varies.

Clinical Reference

1. Hunter Z, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637-1646. doi:10.1182/blood-2013-09-525808

2. Landgren O, Tageja N: MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenstrom's Macroglobulinemia. Leukemia. 2014;28(9):1799-1803. doi:10.1038/leu.2014.88

3. Poulain S, Roumier C, Venet-Caillault A, et al. Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia. Clin Cancer Res. 2016;22(6):1480-1488. doi:10.1158/1078-0432.CCR-15-0646

4. Roccaro A, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123(26):4120-4131. doi:10.1182/blood-2014-03-564583

5. Schmidt J, Federmann B, Schindler N, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015;169(6):795-803. doi:10.1111/bjh.13361

6. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791-2796. doi:10.1182/blood-2014-01-550905

7. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440. doi:10.1056/NEJMoa1501548

8. Xu L, Hunter ZR, Tsakmaklis N, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom macroglobulinaemia. Br J Haematol. 2016;172(5):735-744. doi:10.1111/bjh.13897

Day(s) Performed

Monday through Friday

Report Available

7 to 10 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81479